Norway rejects national life science strategy – sees no need

The Norwegian Arbeiderpartiet rejects a proposal that Norway should develop its own life science strategy.

We desire talent to come here, but are we genuinely welcoming them?

Sweden faces significant challenges in creating a truly inclusive environment that makes international professionals feel welcome, valued, and able to build mea...

Astra Zeneca fryser miljardinvestering i Storbritannien

Astra Zeneca har pausat en planerad investering på motsvarande 2,5 miljarder kronor. Det är det senaste läkemedelsbolaget som drar tillbaka sina satsningar i Storbritannien.

Charlotta Gummeson leaves Sahlgrenska Science Park – “It feels sad and exciting at the same time”

With mixed emotions, Charlotta Gummeson will leave her position as CEO of Sahlgrenska Science Park in October. “It feels sad and exciting at the same time. I’ve...

EMA varnar för icke godkända cellterapier

Icke godkända, och därmed olagliga, avancerade terapiläkemedel marknadsförs till patienter i Europa. Det uppger den europeiska läkemedelsmyndigheten EMA, som nu...

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

Automated dispensing

Are you interested in automated dispensing of liquids?

Your solution for right part positioning

ZEISS OmniFix CT - right part positioning solution to get meaningful measuring results for all part sizes.

Rapid developments in AI – “All stakeholders are struggling to understand it”

Artificial intelligence is being discussed more and more, and developments in the field are moving rapidly. As the Swedish Medical Products Agency testifies, ke...

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

Lundbeck behind the first EU-approved intravenous migraine treatment

A preventive, intravenous treatment for migraines has been approved in the EU for the first time.

Eli Lilly värvar toppforskaren Kaj Blennow – ska leda Alzheimerprojekt

Eli Lilly rekryterar Kaj Blennow, en av Sveriges och världens främsta forskare inom Alzheimers sjukdom, till en post som Vice President of Neuroscience Biomarker Development.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

Automated nitrogen analysis reduces costs per sample

N-Realizer analytical system from C. Gerhardt increases productivity with valve block from Festo

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Pharma Search and Advice AB

Fuskanklagat pharmabolag lägger ner alzheimerprojekt

Amerikanska Cassava Sciences avbryter utvecklingen av sin läkemedelskandidat inom Alzheimers sjukdom efter misslyckande i en fas III-studie

FDA approves new cystic fibrosis therapy

A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).

ZEISS O-INSPECT duo: The multifunctional measuring machine

ZEISS O-INSPECT duo combines advanced microscopy and metrology for impressive measurement accuracy.

Life science trends 2025 – Neurology

New Alzheimer's drugs are beginning to be used in Sweden, more deals in the neuro sector are expected, and tools for deliver active substances across the blood-...

Join the premier metrology and quality assurance event of the year

ZEISS QUALITY INNOVATION SUMMIT in Berlin, October 22-24, 2024.

From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”

A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic ...

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...